ATE446768T1 - Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden - Google Patents

Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden

Info

Publication number: ATE446768T1
Authority: AT; Austria
Prior art keywords: factor vii; compositions; aqueous pharmaceutical; liquid; pharmaceutical composition
Prior art date: 2003-07-01

Application number

AT04738962T

Other languages

English (en)

Inventor

Michael Jensen

Birthe Hansen

Troels Kornfelt

Kirsten Jakobsen

Original Assignee

Novo Nordisk Healthcare Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-01

Filing date

2004-06-30

Publication date

2009-11-15

2004-03-18 Priority claimed from PCT/DK2004/000181 external-priority patent/WO2004082708A2/en

2004-06-30 Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag

2009-11-15 Application granted granted Critical

2009-11-15 Publication of ATE446768T1 publication Critical patent/ATE446768T1/de

Links

229940012413 factor vii Drugs 0.000 title abstract 4
239000007788 liquid Substances 0.000 title abstract 4
239000008194 pharmaceutical composition Substances 0.000 title abstract 3
229920001184 polypeptide Polymers 0.000 title abstract 3
102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
108010023321 Factor VII Proteins 0.000 abstract 4
239000000203 mixture Substances 0.000 abstract 4
102100023804 Coagulation factor VII Human genes 0.000 abstract 3
229910052751 metal Inorganic materials 0.000 abstract 3
239000002184 metal Substances 0.000 abstract 3
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 abstract 2
108010039209 Blood Coagulation Factors Proteins 0.000 abstract 1
102000015081 Blood Coagulation Factors Human genes 0.000 abstract 1
206010008111 Cerebral haemorrhage Diseases 0.000 abstract 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 abstract 1
229940122295 Clotting factor inhibitor Drugs 0.000 abstract 1
102000016519 Coagulation factor VII Human genes 0.000 abstract 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
201000003542 Factor VIII deficiency Diseases 0.000 abstract 1
208000032843 Hemorrhage Diseases 0.000 abstract 1
208000027276 Von Willebrand disease Diseases 0.000 abstract 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
239000003146 anticoagulant agent Substances 0.000 abstract 1
229940127219 anticoagulant drug Drugs 0.000 abstract 1
230000000740 bleeding effect Effects 0.000 abstract 1
239000003114 blood coagulation factor Substances 0.000 abstract 1
239000006172 buffering agent Substances 0.000 abstract 1
230000015556 catabolic process Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
229910052804 chromium Inorganic materials 0.000 abstract 1
239000011651 chromium Substances 0.000 abstract 1
229940105772 coagulation factor vii Drugs 0.000 abstract 1
229910017052 cobalt Inorganic materials 0.000 abstract 1
239000010941 cobalt Substances 0.000 abstract 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 abstract 1
229910052802 copper Inorganic materials 0.000 abstract 1
239000010949 copper Substances 0.000 abstract 1
230000007812 deficiency Effects 0.000 abstract 1
238000006731 degradation reaction Methods 0.000 abstract 1
201000007386 factor VII deficiency Diseases 0.000 abstract 1
208000009429 hemophilia B Diseases 0.000 abstract 1
208000031169 hemorrhagic disease Diseases 0.000 abstract 1
208000014674 injury Diseases 0.000 abstract 1
229910052742 iron Inorganic materials 0.000 abstract 1
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 abstract 1
150000002739 metals Chemical class 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229910052759 nickel Inorganic materials 0.000 abstract 1
239000002736 nonionic surfactant Substances 0.000 abstract 1
230000003647 oxidation Effects 0.000 abstract 1
238000007254 oxidation reaction Methods 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
238000001356 surgical procedure Methods 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
206010043554 thrombocytopenia Diseases 0.000 abstract 1
230000007704 transition Effects 0.000 abstract 1
230000008733 trauma Effects 0.000 abstract 1
208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 abstract 1
239000011701 zinc Substances 0.000 abstract 1
229910052725 zinc Inorganic materials 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

AT04738962T 2003-07-01 2004-06-30 Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden ATE446768T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DKPA200300995		2003-07-01
US48533403P	2003-07-07	2003-07-07
PCT/DK2004/000181 WO2004082708A2 (en)	2003-03-18	2004-03-18	Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
PCT/DK2004/000465 WO2005002615A1 (en)	2003-07-01	2004-06-30	Liquid, aqueous pharmaceutical composition of factor vii polypeptides

Publications (1)

Publication Number	Publication Date
ATE446768T1 true ATE446768T1 (de)	2009-11-15

Family

ID=36697628

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04738962T ATE446768T1 (de)	2003-07-01	2004-06-30	Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden

Country Status (7)

Country	Link
US (2)	US20060166882A1 (de)
EP (1)	EP1644030B1 (de)
JP (2)	JP5306597B2 (de)
AT (1)	ATE446768T1 (de)
DE (1)	DE602004023848D1 (de)
ES (1)	ES2335994T3 (de)
WO (1)	WO2005002615A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2490342C (en)	2002-06-21	2015-06-16	Novo Nordisk A/S	Stabilised solid compositions of factor vii polypeptides
DE602004023848D1 (de) *	2003-07-01	2009-12-10	Novo Nordisk Healthcare Ag	Von factor vii polypeptiden
EP1711513B1 (de)	2003-12-01	2014-07-02	Novo Nordisk Health Care AG	Nanofiltration von faktor vii lösungen zur entfernung von viren
ES2676644T3 (es) *	2003-12-19	2018-07-23	Novo Nordisk Health Care Ag	Composiciones estabilizadas de polipéptidos de factor VII
BRPI0608170A2 (pt) *	2005-04-28	2010-11-09	Novo Nordisk Healthcare Ag	recipiente fechado contendo uma composição de um polipeptìdeo do fator vii ativado, processo para a preparação de um recipiente fechado contendo um polipeptìdeo do fator vii ativado, kit, e, método para a preparação de uma composição farmacêutica
WO2008135500A1 (en)	2007-05-02	2008-11-13	Novo Nordisk Health Care Ag	High concentration factor vii polypeptide formulations comprising an aromatic preservative and an antioxidant
JP2011520999A (ja) *	2008-05-23	2011-07-21	ノボノルディスクヘルスケアアーゲー	高濃度の芳香族保存料を有するペグ官能化セリンプロテアーゼの製剤
US8883979B2 (en)	2012-08-31	2014-11-11	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations
TWI684599B (zh) *	2014-08-12	2020-02-11	美商巴克斯歐塔公司	因子ｘ活化

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2916711A1 (de) *	1979-04-25	1980-11-06	Behringwerke Ag	Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4956386A (en) *	1980-04-25	1990-09-11	Gist-Brocades N.V.	Pharmaceutical compositions and process for their preparation
US4404132A (en) *	1980-05-27	1983-09-13	Cutter Laboratories, Inc.	Blood coagulation promoting product
CA1182748A (en) *	1980-11-21	1985-02-19	Gerard Marx	Method for synthesizing procoagulant factor viii activity
US4495278A (en) *	1981-04-27	1985-01-22	Baxter Travenol Laboratories, Inc.	Process for making novel blood clotting enzyme compositions
US4382083A (en) *	1981-06-25	1983-05-03	Baxter Travenol Laboratories, Inc.	Therapeutic method for treating blood-clotting defects with factor VIIa
GR860984B (en) *	1985-04-17	1986-08-18	Zymogenetics Inc	Expression of factor vii and ix activities in mammalian cells
US5180583A (en) *	1985-11-26	1993-01-19	Hedner Ulla K E	Method for the treatment of bleeding disorders
US5595886A (en) *	1986-01-27	1997-01-21	Chiron Corporation	Protein complexes having Factor VIII:C activity and production thereof
ES2045167T5 (es) *	1987-10-23	1996-07-01	Centre Regional De Transfusion	Preparacion de concentrado de factor ix humano de elevada pureza y de otras proteinas plasmaticas.
US5472850A (en) *	1991-04-10	1995-12-05	Oklahoma Medical Research Foundation	Quantitative clotting assay for activated factor VII
CA2074839C (en) *	1990-01-29	2000-11-14	Kathleen L. Berkner	Modified factor vii anticoagulant proteins
US5997864A (en) *	1995-06-07	1999-12-07	Novo Nordisk A/S	Modified factor VII
US5817788A (en) *	1991-02-28	1998-10-06	Zymogenetics, Inc.	Modified factor VII
US5833982A (en) *	1991-02-28	1998-11-10	Zymogenetics, Inc.	Modified factor VII
DE69333928T2 (de) *	1992-04-30	2006-08-17	Probitas Pharma Inc., Los Angeles	Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes
DK38293D0 (da)	1993-03-31	1993-03-31	Novo Nordisk As	Fremstilling af proteiner
SE9301581D0 (sv) *	1993-05-07	1993-05-07	Kabi Pharmacia Ab	Protein formulation
WO1995003332A1 (en) *	1993-07-23	1995-02-02	Baxter International Inc.	Activated human factor viii and method of preparation
US6277828B1 (en) *	1993-08-20	2001-08-21	Syntex (U.S.A.) Inc.	Pharmaceutical formulations of nerve growth factor
US5576291A (en) *	1993-09-13	1996-11-19	Baxter International Inc.	Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5396670A (en) *	1993-10-08	1995-03-14	Guardian Products, Inc.	Sling for a patient lifter
IL113010A0 (en) *	1994-03-31	1995-10-31	Pharmacia Ab	Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US5580856A (en) *	1994-07-15	1996-12-03	Prestrelski; Steven J.	Formulation of a reconstituted protein, and method and kit for the production thereof
DE4435520A1 (de) *	1994-10-04	1996-04-11	Immuno Ag	Verfahren zur Trennung von rekombinantem pro-Faktor IX von rekombinantem Faktor IX
SE9403915D0 (sv) *	1994-11-14	1994-11-14	Annelie Almstedt	Process A
US5649959A (en) *	1995-02-10	1997-07-22	Sherwood Medical Company	Assembly for sealing a puncture in a vessel
US5993795A (en) *	1995-11-09	1999-11-30	Takemoto Yushi Kabushiki Kaisha	Protein composition derived from sesame seed and use thereof
US6320029B1 (en) *	1996-11-29	2001-11-20	The American National Red Cross	Methods of production and use of liquid formulations of plasma proteins
US5925738A (en) *	1995-12-01	1999-07-20	The American National Red Cross	Methods of production and use of liquid formulations of plasma proteins
US5830852A (en) *	1995-12-19	1998-11-03	Cobra Therapeutics, Ltd.	Compositions for insulin-receptor mediated nucleic acid delivery
US5770700A (en) *	1996-01-25	1998-06-23	Genetics Institute, Inc.	Liquid factor IX formulations
US5763401A (en) *	1996-07-12	1998-06-09	Bayer Corporation	Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US5927739A (en) *	1996-10-07	1999-07-27	Evling; Jens	Dual friction wheelchair hand rim
US5804420A (en) *	1997-04-18	1998-09-08	Bayer Corporation	Preparation of recombinant Factor VIII in a protein free medium
US6461610B1 (en) *	1997-07-18	2002-10-08	Novo Nordisk A/S	Methods for modifying cell motility using factor VIIa or inactivated factor VIIa
US6310183B1 (en) *	1997-09-10	2001-10-30	Novo Nordisk A/S	Coagulation factor VIIa composition
PT2193809E (pt) *	1999-02-22	2015-08-24	Baxter Int	Formulações de fator viii livres de albumina
JP2000247903A (ja) *	1999-03-01	2000-09-12	Chugai Pharmaceut Co Ltd	長期安定化製剤
US20010031721A1 (en) *	1999-05-05	2001-10-18	Chandra Webb	Highly concentrated, lyophilized, and liquid factor IX formulations
JP4674021B2 (ja) *	1999-07-13	2011-04-20	ビオヴィトルム・アクチボラゲット（プブリクト）	安定第ｖｉｉｉ因子組成物
US6586574B1 (en) *	1999-08-17	2003-07-01	Nn A/S	Stabilization of freeze-dried cake
US6750053B1 (en) *	1999-11-15	2004-06-15	I-Stat Corporation	Apparatus and method for assaying coagulation in fluid samples
PL204285B1 (pl) *	2000-02-11	2009-12-31	Bayer Healthcare Llc	Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
JP5090605B2 (ja) *	2000-05-03	2012-12-05	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	凝固因子ｖｉｉの皮下投与
US7015194B2 (en) *	2000-05-10	2006-03-21	Novo Nordisk A/S	Pharmaceutical composition comprising factor VIIa and anti-TFPI
AU9165201A (en) *	2000-10-02	2002-04-15	Novo Nordisk As	Factor vii glycoforms
WO2002038162A1 (en) *	2000-11-09	2002-05-16	The Scripps Research Institute	MODIFIED FACTOR VIIa
DE50114021D1 (de) *	2001-01-08	2008-07-24	Csl Behring Gmbh	Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms
US6825323B2 (en) *	2001-01-10	2004-11-30	The United States Of America As Represented By The Secretary Of The Army	Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
WO2002069838A1 (fr)	2001-03-06	2002-09-12	Atsushi Takahashi	Dispositif collecteur et agitateur melangeur d'os en autogreffe
EP1407780B1 (de) *	2001-07-10	2013-05-01	The Chemo-Sero-Therapeutic Research Institute	Pharmazeutisch stabile hämostatische zusammensetzungen
US6858587B2 (en) *	2001-11-02	2005-02-22	Novo Nordisk Pharmaceuticals, Inc.	Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
US7078479B2 (en) *	2001-11-09	2006-07-18	Novo Nordisk Healthcare A/G	Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
US7125846B2 (en) *	2001-11-09	2006-10-24	Novo Nordisk Healthcare A/G	Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
WO2003039585A1 (en) *	2001-11-09	2003-05-15	Novo Nordisk Health Care Ag	Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
US20030119743A1 (en) *	2001-11-09	2003-06-26	Rasmus Rojkjaer	Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
ES2325653T3 (es) *	2001-12-21	2009-09-11	Novo Nordisk Health Care Ag	Composicion liquida de polipeptidos del factor vii.
KR20040065278A (ko) *	2001-12-21	2004-07-21	노보 노르디스크 에이/에스	변경된 인자 ⅶ 폴리펩티드의 액체 조성물
JP2005530682A (ja) *	2001-12-21	2005-10-13	ノボ　ノルディスク　アクティーゼルスカブ	修飾第ｖｉｉ因子ポリペプチドの液体組成物
US20040009918A1 (en) *	2002-05-03	2004-01-15	Hanne Nedergaard	Stabilised solid compositions of modified factor VII
AU2003230367A1 (en) *	2002-05-10	2003-11-11	Neurocrine Biosciences, Inc.	Substituted piperazine as melanocortin receptors ligands
CA2490342C (en) *	2002-06-21	2015-06-16	Novo Nordisk A/S	Stabilised solid compositions of factor vii polypeptides
FR2841854B1 (fr) *	2002-07-04	2004-09-24	Bosch Gmbh Robert	Dispositif d'assistance de freinage
AT501088A2 (de) *	2002-12-18	2006-06-15	Bio Prod & Bio Eng Ag	Stabile therapeutische proteine
CA2518327A1 (en) *	2003-03-18	2004-09-30	Novo Nordisk Health Care Ag	Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
US7897734B2 (en) *	2003-03-26	2011-03-01	Novo Nordisk Healthcare Ag	Method for the production of proteins
BRPI0409936A (pt) *	2003-05-23	2006-04-25	Novo Nordisk Healthcare Ag	uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico
ATE547114T1 (de) *	2003-06-25	2012-03-15	Novo Nordisk Healthcare Ag	Flüssige zusammensetzungen von factor vii polypeptiden
DE602004023848D1 (de) *	2003-07-01	2009-12-10	Novo Nordisk Healthcare Ag	Von factor vii polypeptiden
WO2005016365A2 (en) *	2003-08-14	2005-02-24	Novo Nordisk Health Care Ag	Liquid, aqueous pharmaceutical composition of factor vii polypeptides
ES2676644T3 (es) *	2003-12-19	2018-07-23	Novo Nordisk Health Care Ag	Composiciones estabilizadas de polipéptidos de factor VII
BRPI0608170A2 (pt) *	2005-04-28	2010-11-09	Novo Nordisk Healthcare Ag	recipiente fechado contendo uma composição de um polipeptìdeo do fator vii ativado, processo para a preparação de um recipiente fechado contendo um polipeptìdeo do fator vii ativado, kit, e, método para a preparação de uma composição farmacêutica

2004
- 2004-06-30 DE DE602004023848T patent/DE602004023848D1/de not_active Expired - Lifetime
- 2004-06-30 JP JP2006515737A patent/JP5306597B2/ja not_active Expired - Fee Related
- 2004-06-30 ES ES04738962T patent/ES2335994T3/es not_active Expired - Lifetime
- 2004-06-30 EP EP04738962A patent/EP1644030B1/de not_active Expired - Lifetime
- 2004-06-30 WO PCT/DK2004/000465 patent/WO2005002615A1/en not_active Ceased
- 2004-06-30 AT AT04738962T patent/ATE446768T1/de not_active IP Right Cessation
2005
- 2005-12-15 US US11/304,427 patent/US20060166882A1/en not_active Abandoned
2009
- 2009-08-06 US US12/536,872 patent/US20100166730A1/en not_active Abandoned
2012
- 2012-03-06 JP JP2012049441A patent/JP2012153696A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP5306597B2 (ja)	2013-10-02
WO2005002615A1 (en)	2005-01-13
EP1644030B1 (de)	2009-10-28
EP1644030A1 (de)	2006-04-12
JP2007507419A (ja)	2007-03-29
DE602004023848D1 (de)	2009-12-10
US20060166882A1 (en)	2006-07-27
JP2012153696A (ja)	2012-08-16
US20100166730A1 (en)	2010-07-01
ES2335994T3 (es)	2010-04-07

Legal Events

Date	Code	Title	Description
2010-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
MXPA05009914A (es)	2006-01-09	Composiciones farmaceuticas acuosas, liquidas de polipeptidos del factor vii.
Verstraete	1985	Clinical application of inhibitors of fibrinolysis
Goodnough et al.	2003	Bloodless medicine: clinical care without allogeneic blood transfusion.
Esmon	2003	The protein C pathway
Karski et al.	1993	Prevention of postbypass bleeding with tranexamic acid and ϵ-aminocaproic acid
EP0748337B1 (de)	1999-06-30	Verfahren zur herstellung eines fibrinogen,faktor xiii und fibronectin enthaltenden biologischen klebstoffes
CA2113663C (en)	2005-06-28	Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation
Koo et al.	1999	Case report. Acute renal cortical necrosis caused by an antifibrinolytic drug (tranexamic acid).
JP2004075682A5 (de)	2006-09-28
TR200101903T2 (tr)	2001-11-21	Yeni malonik asit türevleri, bunların preparasyon işlemleri.
ATE446768T1 (de)	2009-11-15	Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
BG108514A (en)	2005-04-30	METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES
DE69427650D1 (de)	2001-08-09	Verbindungen mit wachstumshormon-freisetzenden eigenschaften
DE3617753A1 (de)	1986-12-04	Gewebe-plasminogenaktivator, diesen enthaltende pharmazeutische formulierungen sowie ihre herstellung und ihre verwendung in der human- und veterinaermedizin
Levy	2004	Hemostatic agents.
AT500670A1 (de)	2006-02-15	Arzneimittel zur lokalen anwendung
KR940005671A (ko)	1994-03-22	비트로넥틴으로부터 유도된 합성 펩티드와 그것을 포함하는 제약 조성물
Kuklo et al.	2003	Perioperative blood and blood product management for spinal deformity surgery
Biesma et al.	1993	The efficacy of subcutaneous recombinant human erythropoietin in the correction of phlebotomy‐induced anemia in autologous blood donors
JP2004511492A5 (de)	2005-03-17
ATE303816T1 (de)	2005-09-15	Neue therapeutische verwendung eines eine virale ansteckung modulierendes protein zur verhinderung von abstossung von fremdtransplantaten
JPWO1994002165A1 (ja)	1994-08-04	Ｔｃｆ−１１を有効成分とする血液凝固正常化剤
D'Ambra et al.	1990	Aprotinin, erythropoietin, and blood substitutes
ATE433743T1 (de)	2009-07-15	Ternäre eutektische gemische von lokalanaesthetika
WO2017117995A1 (zh)	2017-07-13	一种含有壳聚糖的蛋白胶及其使用方法